Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arrowhead Pharmaceuticals, Inc. (ARWR)
USD74.11
-2.29 (-3.00%)
US NASDAQ Healthcare Biotechnology
Address
177 East Colorado Boulevard 91105
Pasadena, CA, US
Pasadena, CA, US
CEO
Christopher R. Anzalone
Website
arrowheadpharma.com
IPO
1993-12-16
CIK 879407 ISIN US04280A1007
Also trades on
London Stock Exchange · 0HI3.L (USD)
NASDAQ Global Select · ARWR (USD)
Description
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD74.11
-2.29 (-3.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.27
Float Shares
122.04M
Free Float %
87.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.67% | +3.32% | +23.91% | +23.85% | +92.12% | +19.05% | +417.28% | +98.14% | +16.44% | +1,411.28% | -97.30% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (20 ratings, all time)
Buy
Price Targets & DCF
Current price
74.11
Low
35.00
-52.8%
Consensus
82.33
+11.1%
Median
90.00
+21.4%
High
110.00
+48.4%
Ratings Trend (MoM)
85% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | +1 |
| Buy | 7 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
100.00
+34.9%
|
| Last Quarter | 1 |
100.00
+34.9%
|
| Last Year | 14 |
80.21
+8.2%
|
| All Time | 27 |
59.84
-19.3%
|
Quality scores
Altman Z-Score
3.69
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+23,258.2% ★ Q1'26: -86.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+99.8% ★ Q1'26: -133.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+1.6% Q1'26: +111.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+17.0% ★ Q1'26: -191.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -300.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+11.7% Q1'26: +5.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.22× ★ Q1'26: -2.55× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2014 actual |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 11 Rev. Ana. 10 EPS Ana. |
Sep 2027 10 Rev. Ana. 10 EPS Ana. |
Sep 2028 10 Rev. Ana. 8 EPS Ana. |
Sep 2029 5 Rev. Ana. 3 EPS Ana. |
Sep 2030 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
175.0K
est: 235.9K (-25.8%)
|
382.0K
est: 484.3K (-21.1%)
|
158.3K
est: 741.6K (-78.6%)
|
31.41M
est: 30.72M (+2.2%)
|
16.14M
est: 59.12M (-72.7%)
|
168.80M
est: 165.95M (+1.7%)
|
87.99M
est: 132.14M (-33.4%)
|
138.29M
est: 134.59M (+2.7%)
|
243.23M
est: 255.58M (-4.8%)
|
240.74M
est: 35.47M (+578.6%)
|
3.55M
est: 62.14M (-94.3%)
|
829.45M
est: 764.56M (+8.5%)
|
470.89M
371.51M – 670.80M
-38.4% YoY
|
335.41M
157.14M – 507.36M
-28.8% YoY
|
599.39M
582.83M – 615.95M
+78.7% YoY
|
868.66M
580.32M – 1.28B
+44.9% YoY
|
1.69B
1.13B – 2.49B
+94.7% YoY
|
| EBITDA |
-49.76M
est: -49.60M (-0.3%)
|
-93.64M
est: -313.6K (-29,762.1%)
|
-76.43M
est: -480.1K (-15,819.1%)
|
-32.31M
est: -19.89M (-62.4%)
|
-51.24M
est: -38.27M (-33.9%)
|
65.63M
est: 61.30M (+7.1%)
|
-87.22M
est: -334.90M (+74.0%)
|
-132.58M
est: -333.04M (+60.2%)
|
-162.29M
est: -58.78M (-176.1%)
|
-175.67M
est: -22.40M (-684.3%)
|
-561.51M
est: -39.24M (-1,331.1%)
|
164.82M
est: -482.73M (+134.1%)
|
-297.32M
-423.53M – -234.57M
+38.4% YoY
|
-211.77M
-320.34M – -99.21M
+28.8% YoY
|
-378.45M
-388.91M – -368.00M
-78.7% YoY
|
-548.46M
-807.75M – -366.41M
-44.9% YoY
|
-1.07B
-1.57B – -713.40M
-94.7% YoY
|
| EBIT |
-51.10M
est: -52.17M (+2.0%)
|
-95.97M
est: -326.7K (-29,273.0%)
|
-79.69M
est: -500.3K (-15,828.8%)
|
-37.00M
est: -20.73M (-78.5%)
|
-55.94M
est: -39.88M (-40.3%)
|
61.19M
est: 47.74M (+28.2%)
|
-93.16M
est: -376.17M (+75.2%)
|
-140.85M
est: -359.29M (+60.8%)
|
-172.71M
est: -124.48M (-38.7%)
|
-188.17M
est: -23.57M (-698.4%)
|
-580.11M
est: -41.28M (-1,305.1%)
|
140.89M
est: -507.94M (+127.7%)
|
-312.85M
-445.65M – -246.82M
+38.4% YoY
|
-222.83M
-337.07M – -104.40M
+28.8% YoY
|
-398.21M
-409.22M – -387.21M
-78.7% YoY
|
-577.11M
-849.94M – -385.54M
-44.9% YoY
|
-1.12B
-1.65B – -750.66M
-94.7% YoY
|
| Net Income |
-58.63M
est: -50.48M (-16.2%)
|
-91.94M
est: -215.35M (+57.3%)
|
-81.72M
est: -172.28M (+52.6%)
|
-34.38M
est: -56.51M (+39.2%)
|
-54.45M
est: -11.70M (-365.2%)
|
67.98M
est: 56.24M (+20.9%)
|
-84.55M
est: -352.71M (+76.0%)
|
-140.85M
est: -349.03M (+59.6%)
|
-176.06M
est: -98.54M (-78.7%)
|
-205.28M
est: -470.79M (+56.4%)
|
-599.49M
est: -594.79M (-0.8%)
|
-1.63M
est: 33.03M (-104.9%)
|
-434.20M
-531.49M – -156.77M
-1,414.4% YoY
|
-595.99M
-905.15M – -247.42M
-37.3% YoY
|
-417.28M
-675.27M – 120.38M
+30.0% YoY
|
-226.00M
-364.89M – -128.48M
+45.8% YoY
|
381.49M
216.87M – 615.94M
+268.8% YoY
|
| SGA |
24.33M
est: 1.36M (+1,685.4%)
|
34.72M
est: 2.80M (+1,140.6%)
|
41.00M
est: 4.28M (+856.8%)
|
17.46M
est: 177.53M (-90.2%)
|
19.08M
est: 341.59M (-94.4%)
|
26.54M
est: 34.33M (-22.7%)
|
51.66M
est: 123.90M (-58.3%)
|
80.08M
est: 777.67M (-89.7%)
|
122.82M
est: 1.48B (-91.7%)
|
90.93M
est: 204.96M (-55.6%)
|
96.82M
est: 358.86M (-73.0%)
|
121.92M
est: 4.42B (-97.2%)
|
2.72B
2.15B – 3.87B
-38.4% YoY
|
1.94B
907.44M – 2.93B
-28.8% YoY
|
3.46B
3.37B – 3.56B
+78.7% YoY
|
5.02B
3.35B – 7.39B
+44.9% YoY
|
9.77B
6.52B – 14.38B
+94.7% YoY
|
| EPS |
-1.25
est: -0.74 (-68.9%)
|
-1.60
est: -1.61 (+0.6%)
|
-1.34
est: -1.29 (-4.0%)
|
-0.47
est: -0.42 (-11.2%)
|
-0.65
est: -0.09 (-642.9%)
|
0.72
est: 0.76 (-4.8%)
|
-0.84
est: -0.25 (-230.4%)
|
-1.36
est: -0.69 (-96.3%)
|
-1.67
est: -1.38 (-21.1%)
|
-1.91
est: -4.23 (+54.9%)
|
-5.00
est: -4.70 (-6.4%)
|
-0.01
est: 0.09 (-113.8%)
|
-3.03
-3.97 – -1.17
-3,528.3% YoY
|
-4.15
-6.77 – -1.85
-36.9% YoY
|
-2.85
-5.05 – 0.90
+31.3% YoY
|
-1.69
-2.73 – -0.96
+40.7% YoY
|
2.85
1.62 – 4.60
+268.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | Morgan Stanley | Equal Weight | Overweight | Upgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
11.96M
OE per share TTM
0.16
Owner's Yield
0.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
87.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
117
Total invested
313.62M
Insider transactions (90d)
2
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 12.71M | 12.00% | — | — | — | — | HC | Delaware | 2023-01-20 | ↗ |
| 2 | The Vanguard Group - 23-1945930 | 9.64M | 9.22% | — | 192.0K | 9.36M | 281.4K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 3 | Avoro Capital Advisors LLC | 8.89M | 7.20% | 8.89M | — | 8.89M | — | IA, OO | Delaware | 2024-11-14 | ↗ |
| 4 | Behzad Aghazadeh | 8.89M | 7.20% | 8.89M | — | 8.89M | — | IN | Delaware | 2024-11-14 | ↗ |
| 5 | OppenheimerFunds, Inc. | 7.81M | 8.46% | — | 7.81M | — | — | IA | Colorado | 2019-01-14 | ↗ |
| 6 | STATE STREET CORPORATION | 6.35M | 5.10% | — | 5.94M | — | — | HC | MA | 2024-10-16 | ↗ |
| 7 | Baker Bros. Advisors (GP) LLC | 3.68M | 5.90% | 3.68M | — | 3.68M | — | HC | Delaware | 2016-02-16 | ↗ |
| 8 | Baker Bros. Advisors LP | 3.68M | 5.90% | 3.68M | — | 3.68M | — | IA | Delaware | 2016-02-16 | ↗ |
| 9 | Felix J. Baker | 3.68M | 5.90% | 3.68M | — | 3.68M | — | IN | Delaware | 2016-02-16 | ↗ |
| 10 | Julian C. Baker | 3.68M | 5.90% | 3.68M | — | 3.68M | — | IN | Delaware | 2016-02-16 | ↗ |
| 11 | 10. | 3.12M | 5.90% | — | 3.12M | — | 3.12M | PN | Delaware | 2014-10-14 | ↗ |
| 12 | Oppenheimer Global Opportunities Fund | 3.00M | 5.04% | — | 3.00M | — | — | IV | Colorado | 2016-02-01 | ↗ |
| 13 | Point72 Capital Advisors, Inc. (formerly S.A.C. Capital Advisors, Inc.) | 2.79M | 6.20% | — | 2.79M | — | — | CO | Delaware | 2014-04-09 | ↗ |
| 14 | Millennium Management LLC | 2.22M | 4.90% | — | 2.22M | — | 2.22M | OO | Delaware | 2014-04-08 | ↗ |
| 15 | Integrated Core Strategies (US) LLC | 1.34M | 3.00% | — | 1.34M | — | 1.34M | OO | Delaware | 2014-04-08 | ↗ |
| 16 | Cubist Systematic Strategies, LLC | 6.7K | 4.00% | — | 6.7K | — | — | OO | Delaware | 2015-02-17 | ↗ |
| 17 | Steven A. Cohen | 6.7K | 4.00% | — | 6.7K | — | — | IN | Delaware | 2015-02-17 | ↗ |
| 18 | EverPoint Asset Management, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2015-02-17 | ↗ |
| 19 | Investments, LP | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2020-02-14 | ↗ |
| 20 | Peter Kolchinsky | — | 0.00% | — | — | — | — | IN | Massachusetts | 2015-02-17 | ↗ |
| 21 | Point72 Asset Management, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2015-02-17 | ↗ |
| 22 | Point72 Capital Advisors, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 2015-02-17 | ↗ |
| 23 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Massachusetts | 2015-02-17 | ↗ |
| 24 | RA Capital Management, LLC | — | 0.00% | — | — | — | — | IA | Massachusetts | 2015-02-17 | ↗ |
| 25 | S | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2020-02-14 | ↗ |
| 26 | S.A.C. Capital Advisors, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2014-04-09 | ↗ |
| 27 | Sigma Capital Management, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2014-04-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
117
-303 vs prev Q
New positions
24
Closed positions
311
Increased
64
Reduced
29
Put/Call ratio
0.00
Calls held
500.00
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 21.32M +1.1M (+5.4%) | 1.42B +717.8M (+102.9%) | 15.22% +0.676 pp | 0.02% +0.012 pp | USD21.20 +213.2% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 15.29M -742.7K (-4.6%) | 1.02B +462.2M (+83.6%) | 10.92% -0.614 pp | 0.01% +0.006 pp | USD22.28 +198.0% | 39 qtrs — |
| 3 | AVORO CAPITAL ADVISORS LLC | 10.63M -275.0K (-2.5%) | 705.39M +329.5M (+87.6%) | 7.59% -0.253 pp | 6.78% +1.922 pp | USD26.84 +147.4% | 11 qtrs — |
| 4 | FMR LLC | 6.52M +760.6K (+13.2%) | 432.89M +234.2M (+117.9%) | 4.66% +0.513 pp | 0.02% +0.012 pp | USD30.57 +117.2% | 30 qtrs — |
| 5 | STATE STREET CORP | 6.40M +6.5K (+0.1%) | 425.15M +204.5M (+92.7%) | 4.57% -0.029 pp | 0.01% +0.007 pp | USD25.59 +159.4% | 40 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 3.26M +133.9K (+4.3%) | 216.80M +108.8M (+100.7%) | 2.33% +0.079 pp | 0.01% +0.007 pp | USD29.42 +125.7% | 39 qtrs — |
| 7 | SLATE PATH CAPITAL LP | 2.52M -2.5M (-49.3%) | 167.54M -4.3M (-2.5%) | 1.80% -1.781 pp | 2.26% -0.399 pp | USD26.95 +146.3% | 9 qtrs — |
| 8 | BAKER BROS. ADVISORS LP | 2.18M +504.9K (+30.2%) | 144.44M +86.8M (+150.7%) | 1.55% +0.352 pp | 0.85% +0.429 pp | USD33.82 +96.3% | 3 qtrs — |
| 9 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2.09M +6.3K (+0.3%) | 138.62M +66.8M (+93.1%) | 1.49% -0.006 pp | 0.08% +0.036 pp | USD34.01 +95.2% | 3 qtrs — |
| 10 | FRED ALGER MANAGEMENT, LLC | 1.83M +1.5M (+497.4%) | 121.69M +111.1M (+1,049.9%) | 1.31% +1.088 pp | 0.48% +0.436 pp | USD61.05 +8.7% | 2 qtrs — |
| 11 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1.83M +839.9K (+84.6%) | 121.69M +87.4M (+255.3%) | 1.31% +0.595 pp | 1.55% +1.031 pp | USD49.11 +35.2% | 2 qtrs — |
| 12 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.77M -330.1K (-15.7%) | 117.47M +45.1M (+62.2%) | 1.26% -0.247 pp | 0.80% +0.279 pp | USD34.49 +92.5% | 2 qtrs — |
| 13 | NORGES BANK | 1.70M +1.7M (+100.0%) | 113.16M +113.2M (+100.0%) | 1.22% +1.217 pp | 0.01% +0.012 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 14 | GOLDMAN SACHS GROUP INC | 1.68M -96.4K (-5.4%) | 111.37M +50.2M (+82.0%) | 1.20% -0.078 pp | 0.01% +0.006 pp | USD25.07 +164.8% | 39 qtrs — |
| 15 | SIREN, L.L.C. | 1.50M -1.2M (-43.8%) | 99.62M +7.5M (+8.2%) | 1.07% -0.849 pp | 2.97% -0.631 pp | USD19.28 +244.3% | 6 qtrs — |
| 16 | MORGAN STANLEY | 1.48M -226.7K (-13.3%) | 97.99M +39.3M (+66.9%) | 1.05% -0.171 pp | 0.01% +0.002 pp | USD27.26 +143.5% | 39 qtrs — |
| 17 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.35M +7.9K (+0.6%) | 89.87M +43.5M (+93.6%) | 0.97% -0.001 pp | 0.01% +0.007 pp | USD28.34 +134.3% | 39 qtrs — |
| 18 | NORTHERN TRUST CORP | 1.35M +34.7K (+2.6%) | 89.38M +44.1M (+97.6%) | 0.96% +0.018 pp | 0.01% +0.006 pp | USD24.30 +173.2% | 39 qtrs — |
| 19 | FISHER ASSET MANAGEMENT, LLC | 1.31M +257.9K (+24.5%) | 87.09M +50.7M (+139.6%) | 0.94% +0.179 pp | 0.03% +0.017 pp | USD34.00 +95.3% | 7 qtrs — |
| 20 | JANUS HENDERSON GROUP PLC | 1.28M +306.9K (+31.5%) | 85.00M +51.5M (+153.5%) | 0.91% +0.214 pp | 0.04% +0.023 pp | USD42.31 +56.9% | 23 qtrs — |
| 21 | UBS ASSET MANAGEMENT AMERICAS INC | 1.26M -499.1K (-28.4%) | 83.68M +23.0M (+37.9%) | 0.90% -0.366 pp | 0.02% +0.005 pp | USD19.75 +236.2% | 31 qtrs — |
| 22 | PICTET ASSET MANAGEMENT HOLDING SA | 1.03M +737.7K (+253.5%) | 68.64M +58.8M (+597.3%) | 0.76% +0.549 pp | 0.07% +0.057 pp | USD51.71 +28.4% | 10 qtrs — |
| 23 | UBS GROUP AG | 987.3K +69.1K (+7.5%) | 65.55M +33.9M (+107.0%) | 0.71% +0.045 pp | 0.01% +0.006 pp | USD25.29 +162.5% | 39 qtrs — |
| 24 | VESTAL POINT CAPITAL, LP | 900.0K +900.0K (+100.0%) | 59.75M +59.8M (+100.0%) | 0.64% +0.643 pp | 2.03% +2.032 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 25 | BANK OF NEW YORK MELLON CORP | 887.8K +73.3K (+9.0%) | 58.94M +30.9M (+109.8%) | 0.63% +0.048 pp | 0.01% +0.005 pp | USD29.68 +123.7% | 39 qtrs — |
| 26 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 859.9K +325.8K (+61.0%) | 57.09M +38.7M (+209.9%) | 0.61% +0.230 pp | 0.01% +0.005 pp | USD45.62 +45.5% | 39 qtrs — |
| 27 | PRICE T ROWE ASSOCIATES INC /MD/ | 838.8K +728.6K (+660.9%) | 55.69M +51.9M (+1,364.4%) | 0.60% +0.520 pp | 0.01% +0.006 pp | USD61.08 +8.7% | 39 qtrs — |
| 28 | WESTERN FINANCIAL CORP/CA | 820.2K +— (+0.0%) | 54.46M +26.2M (+92.5%) | 0.60% +0.015 pp | 21.60% +9.286 pp | USD40.56 +63.7% | 13 qtrs — |
| 29 | PRINCIPAL FINANCIAL GROUP INC | 715.5K -64.6K (-8.3%) | 47.50M +20.6M (+76.6%) | 0.53% -0.034 pp | 0.02% +0.011 pp | USD26.31 +152.3% | 31 qtrs — |
| 30 | ASSENAGON ASSET MANAGEMENT S.A. | 684.9K +304.3K (+79.9%) | 45.47M +32.3M (+246.4%) | 0.50% +0.231 pp | 0.06% +0.045 pp | USD48.17 +37.8% | 12 qtrs — |
| 31 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 663.3K +538.7K (+432.6%) | 44.03M +39.7M (+925.2%) | 0.47% +0.384 pp | 0.12% +0.102 pp | USD60.40 +9.9% | 2 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 622.0K -138.7K (-18.2%) | 41.30M +15.1M (+57.4%) | 0.44% -0.103 pp | 0.00% +0.001 pp | USD25.90 +156.3% | 39 qtrs — |
| 33 | JPMORGAN CHASE & CO | 611.9K -163.8K (-21.1%) | 40.62M +13.9M (+51.8%) | 0.46% -0.100 pp | 0.00% +0.001 pp | USD45.21 +46.8% | 39 qtrs — |
| 34 | RTW INVESTMENTS, LP | 584.7K +584.7K (+100.0%) | 38.82M +38.8M (+100.0%) | 0.42% +0.418 pp | 0.39% +0.389 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 35 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 550.0K +550.0K (+100.0%) | 36.51M +36.5M (+100.0%) | 0.39% +0.393 pp | 0.06% +0.055 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 36 | INVESCO LTD. | 547.8K +44.9K (+8.9%) | 36.37M +19.0M (+109.7%) | 0.39% +0.029 pp | 0.01% +0.003 pp | USD21.97 +202.2% | 31 qtrs — |
| 37 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 478.5K -60.8K (-11.3%) | 31.77M +13.2M (+70.8%) | 0.34% -0.046 pp | 0.11% +0.039 pp | USD17.38 +282.0% | 4 qtrs — |
| 38 | CITADEL ADVISORS LLC | 474.3K +156.6K (+49.3%) | 31.49M +20.5M (+187.4%) | 0.34% +0.110 pp | 0.00% +0.003 pp | USD42.85 +54.9% | 34 qtrs — |
| 39 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 470.0K +470.0K (+100.0%) | 31.20M +31.2M (+100.0%) | 0.34% +0.336 pp | 0.65% +0.649 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 40 | VOYA INVESTMENT MANAGEMENT LLC | 422.7K +285.2K (+207.4%) | 28.07M +23.3M (+491.7%) | 0.30% +0.203 pp | 0.03% +0.023 pp | USD55.26 +20.1% | 31 qtrs — |
| 41 | WOODLINE PARTNERS LP | 400.2K -600.0K (-60.0%) | 26.57M -7.9M (-23.0%) | 0.29% -0.434 pp | 0.10% -0.059 pp | USD27.02 +145.7% | 12 qtrs — |
| 42 | PRIVIUM FUND MANAGEMENT B.V. | 398.2K -75.7K (-16.0%) | 26.44M +10.1M (+61.7%) | 0.29% -0.047 pp | 4.87% +1.929 pp | USD32.09 +106.9% | 17 qtrs — |
| 43 | LEGAL & GENERAL GROUP PLC | 395.3K +8.9K (+2.3%) | 26.24M +12.9M (+96.9%) | 0.28% +0.004 pp | 0.01% +0.003 pp | USD29.58 +124.4% | 31 qtrs — |
| 44 | BALYASNY ASSET MANAGEMENT L.P. | 376.2K -416.8K (-52.6%) | 24.98M -2.4M (-8.7%) | 0.27% -0.302 pp | 0.03% -0.003 pp | USD34.49 +92.5% | 6 qtrs — |
| 45 | ALYESKA INVESTMENT GROUP, L.P. | 375.4K +375.4K (+100.0%) | 24.92M +24.9M (+100.0%) | 0.27% +0.268 pp | 0.07% +0.070 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 46 | EVENTIDE ASSET MANAGEMENT, LLC | 370.0K +370.0K (+100.0%) | 24.56M +24.6M (+100.0%) | 0.26% +0.264 pp | 0.38% +0.384 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 47 | RHUMBLINE ADVISERS | 352.4K -18.7K (-5.0%) | 23.40M +10.6M (+82.8%) | 0.25% -0.015 pp | 0.02% +0.009 pp | USD27.02 +145.7% | 31 qtrs — |
| 48 | NORDEA INVESTMENT MANAGEMENT AB | 324.3K -48.0K (-12.9%) | 21.57M +8.9M (+70.3%) | 0.24% -0.029 pp | 0.02% +0.007 pp | USD38.58 +72.1% | 20 qtrs — |
| 49 | BARCLAYS PLC | 321.8K +45.2K (+16.3%) | 21.37M +16.0M (+298.8%) | 0.23% +0.031 pp | 0.01% +0.004 pp | USD27.29 +143.3% | 39 qtrs — |
| 50 | NUVEEN, LLC | 288.6K +10.2K (+3.7%) | 19.16M +9.6M (+99.6%) | 0.21% +0.006 pp | 0.01% +0.003 pp | USD14.64 +353.5% | 4 qtrs — |
| 51 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 288.5K -114.1K (-28.3%) | 19.15M +5.3M (+37.9%) | 0.21% -0.084 pp | 0.07% +0.021 pp | USD34.49 +92.5% | 2 qtrs — |
| 52 | ABRDN PLC | 286.1K -234.5K (-45.0%) | 19.00M +1.0M (+5.8%) | 0.21% -0.164 pp | 0.03% +0.001 pp | USD17.04 +289.6% | 7 qtrs — |
| 53 | FENGHE FUND MANAGEMENT PTE. LTD. | 266.7K +266.7K (+100.0%) | 17.71M +17.7M (+100.0%) | 0.20% +0.197 pp | 1.00% +0.997 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 54 | AMERIPRISE FINANCIAL INC | 257.5K -16.7K (-6.1%) | 17.09M +7.6M (+80.8%) | 0.18% -0.013 pp | 0.00% +0.002 pp | USD28.09 +136.3% | 31 qtrs — |
| 55 | TREXQUANT INVESTMENT LP | 250.9K +250.9K (+100.0%) | 16.66M +16.7M (+100.0%) | 0.18% +0.179 pp | 0.15% +0.149 pp | USD66.39 +0.0% | 7 qtrs — |
| 56 | SWISS NATIONAL BANK | 245.4K +31.3K (+14.6%) | 16.29M +8.9M (+120.6%) | 0.18% +0.021 pp | 0.01% +0.005 pp | USD31.58 +110.2% | 31 qtrs — |
| 57 | DEUTSCHE BANK AG\ | 242.1K -4.0K (-1.6%) | 16.07M +7.6M (+89.4%) | 0.18% +0.004 pp | 0.01% +0.002 pp | USD44.54 +49.1% | 39 qtrs — |
| 58 | CAPTION MANAGEMENT, LLC | 239.9K +239.9K (+100.0%) | 15.93M +15.9M (+100.0%) | 0.17% +0.171 pp | 0.11% +0.109 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 59 | FIRST TRUST ADVISORS LP | 237.7K +29.8K (+14.3%) | 15.78M +8.6M (+120.1%) | 0.17% +0.020 pp | 0.01% +0.006 pp | USD38.49 +72.5% | 2 qtrs — |
| 60 | CLEARBRIDGE INVESTMENTS, LLC | 208.1K -183.1K (-46.8%) | 13.81M +322.3K (+2.4%) | 0.15% -0.133 pp | 0.01% +0.001 pp | USD13.31 +398.8% | 4 qtrs — |
| 61 | RAYMOND JAMES FINANCIAL INC | 198.4K -28.9K (-12.7%) | 13.17M +5.3M (+68.0%) | 0.14% -0.022 pp | 0.00% +0.002 pp | USD20.95 +216.9% | 5 qtrs — |
| 62 | HILLSDALE INVESTMENT MANAGEMENT INC. | 193.9K +193.9K (+100.0%) | 12.87M +12.9M (+100.0%) | 0.14% +0.145 pp | 0.36% +0.355 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 63 | PINNACLE ASSOCIATES LTD | 191.7K -11.6K (-5.7%) | 12.72M +5.7M (+81.5%) | 0.14% -0.005 pp | 0.16% +0.070 pp | USD13.76 +382.5% | 4 qtrs — |
| 64 | ALLIANCEBERNSTEIN L.P. | 172.7K +16.8K (+10.8%) | 11.46M +6.1M (+113.2%) | 0.12% +0.011 pp | 0.00% +0.002 pp | USD54.26 +22.4% | 31 qtrs — |
| 65 | PEAK6 LLC | 171.2K +94.1K (+122.0%) | 11.37M +8.7M (+327.4%) | 0.12% +0.067 pp | 0.02% +0.017 pp | USD52.02 +27.6% | 2 qtrs — |
| 66 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 159.5K -1.4K (-0.9%) | 10.59M +5.0M (+90.8%) | 0.12% +0.002 pp | 0.02% +0.008 pp | USD34.49 +92.5% | 4 qtrs — |
| 67 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 159.5K +159.5K (+100.0%) | 10.59M +10.6M (+100.0%) | 0.11% +0.114 pp | 0.04% +0.043 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 68 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 158.6K -114.4K (-41.9%) | 10.53M +1.1M (+11.9%) | 0.11% -0.083 pp | 0.07% +0.010 pp | USD23.57 +181.7% | 12 qtrs — |
| 69 | WELLS FARGO & COMPANY/MN | 152.5K +72.3K (+90.1%) | 10.12M +7.4M (+265.9%) | 0.11% +0.051 pp | 0.00% +0.001 pp | USD43.79 +51.6% | 39 qtrs — |
| 70 | PRUDENTIAL FINANCIAL INC | 152.2K +15.6K (+11.4%) | 10.11M +5.4M (+114.4%) | 0.11% +0.010 pp | 0.01% +0.007 pp | USD22.86 +190.4% | 28 qtrs — |
| 71 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 149.8K +1.3K (+0.9%) | 9.94M +4.8M (+94.2%) | 0.11% +0.004 pp | 0.02% +0.009 pp | USD32.71 +103.0% | 27 qtrs — |
| 72 | DIMENSIONAL FUND ADVISORS LP | 147.4K -327.1K (-68.9%) | 9.79M -6.6M (-40.2%) | 0.11% -0.236 pp | 0.00% -0.002 pp | USD20.04 +231.3% | 26 qtrs — |
| 73 | AQR CAPITAL MANAGEMENT LLC | 147.4K +4.5K (+3.2%) | 9.78M +4.9M (+98.6%) | 0.11% +0.003 pp | 0.01% +0.002 pp | USD16.57 +300.7% | 4 qtrs — |
| 74 | D. E. SHAW & CO., INC. | 146.1K +125.8K (+619.5%) | 9.70M +9.0M (+1,285.0%) | 0.10% +0.090 pp | 0.01% +0.005 pp | USD61.96 +7.1% | 2 qtrs — |
| 75 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 144.5K +144.5K (+100.0%) | 9.59M +9.6M (+100.0%) | 0.10% +0.103 pp | 0.90% +0.897 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 76 | WEALTH EFFECTS LLC | 143.3K -25.2K (-14.9%) | 9.51M +3.7M (+63.8%) | 0.11% -0.016 pp | 2.98% +1.107 pp | USD57.44 +15.6% | 17 qtrs — |
| 77 | WCM INVESTMENT MANAGEMENT, LLC | 138.9K +138.9K (+100.0%) | 9.34M +9.3M (+100.0%) | 0.10% +0.099 pp | 0.02% +0.019 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 78 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 133.9K -4.1K (-3.0%) | 8.89M +4.1M (+87.0%) | 0.10% -0.004 pp | 0.01% +0.006 pp | USD25.06 +164.9% | 7 qtrs — |
| 79 | HIGHTOWER ADVISORS, LLC | 133.2K +340.0 (+0.3%) | 8.85M +4.3M (+93.0%) | 0.10% +0.004 pp | 0.01% +0.005 pp | USD26.24 +153.0% | 30 qtrs — |
| 80 | JANE STREET GROUP, LLC | 132.4K +109.4K (+475.7%) | 8.79M +8.0M (+1,008.1%) | 0.09% +0.078 pp | 0.00% +0.001 pp | USD57.77 +14.9% | 5 qtrs — |
| 81 | MARSHALL WACE, LLP | 123.9K -1.3M (-91.4%) | 8.22M -41.3M (-83.4%) | 0.09% -0.945 pp | 0.01% -0.043 pp | USD15.88 +318.1% | 5 qtrs — |
| 82 | RUSSELL INVESTMENTS GROUP, LTD. | 122.1K +109.2K (+847.8%) | 8.11M +7.7M (+1,724.3%) | 0.09% +0.078 pp | 0.01% +0.008 pp | USD63.32 +4.8% | 28 qtrs — |
| 83 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 118.8K -11.2K (-8.6%) | 7.88M +3.5M (+79.6%) | 0.08% -0.009 pp | 0.01% +0.007 pp | USD38.37 +73.0% | 31 qtrs — |
| 84 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 118.4K +14.4K (+13.8%) | 7.86M +4.3M (+119.1%) | 0.08% +0.010 pp | 0.01% +0.004 pp | USD24.57 +170.2% | 31 qtrs — |
| 85 | SEI INVESTMENTS CO | 112.3K +98.7K (+724.6%) | 7.45M +7.0M (+1,487.1%) | 0.08% +0.070 pp | 0.01% +0.007 pp | USD59.93 +10.8% | 4 qtrs — |
| 86 | WEISS ASSET MANAGEMENT LP | 111.4K +111.4K (+100.0%) | 7.39M +7.4M (+100.0%) | 0.08% +0.080 pp | 0.10% +0.104 pp | USD66.39 +0.0% | 1 qtrs NEW |
| 87 | FRANKLIN RESOURCES INC | 107.4K -9.1K (-7.8%) | 7.13M +3.1M (+77.4%) | 0.08% -0.007 pp | 0.00% +0.001 pp | USD21.46 +209.4% | 8 qtrs — |
| 88 | NEUBERGER BERMAN GROUP LLC | 100.4K +87.0K (+650.0%) | 6.66M +6.2M (+1,343.6%) | 0.07% +0.062 pp | 0.01% +0.005 pp | USD59.78 +11.1% | 3 qtrs — |
| 89 | LPL FINANCIAL LLC | 100.3K +50.1K (+99.9%) | 6.66M +4.9M (+284.8%) | 0.07% +0.036 pp | 0.00% +0.001 pp | USD46.67 +42.3% | 26 qtrs — |
| 90 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 100.0K -125.0K (-55.6%) | 6.64M -1.1M (-14.4%) | 0.07% -0.090 pp | 0.33% -0.195 pp | USD34.49 +92.5% | 5 qtrs — |
| 91 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 98.2K +35.2K (+55.8%) | 6.55M +4.4M (+201.3%) | 0.07% +0.025 pp | 0.01% +0.004 pp | USD51.50 +28.9% | 39 qtrs — |
| 92 | TFG ASSET MANAGEMENT GP LTD | 96.9K +15.1K (+18.4%) | 6.44M +3.6M (+128.0%) | 0.07% +0.010 pp | 1.36% +0.979 pp | USD39.46 +68.2% | 2 qtrs — |
| 93 | THRIVENT FINANCIAL FOR LUTHERANS | 95.0K -4.7K (-4.8%) | 6.31M +2.9M (+83.3%) | 0.07% -0.002 pp | 0.01% +0.004 pp | USD22.56 +194.3% | 27 qtrs — |
| 94 | VICTORY CAPITAL MANAGEMENT INC | 92.6K +47.5K (+105.1%) | 6.15M +4.6M (+294.7%) | 0.07% +0.034 pp | 0.00% +0.003 pp | USD44.14 +50.4% | 38 qtrs — |
| 95 | PLATINUM INVESTMENT MANAGEMENT LTD | 89.5K -21.5K (-19.4%) | 5.94M +2.1M (+55.1%) | 0.06% -0.016 pp | 1.37% +1.126 pp | USD24.93 +166.3% | 12 qtrs — |
| 96 | RAFFERTY ASSET MANAGEMENT, LLC | 84.5K -29.9K (-26.1%) | 5.61M +1.7M (+42.2%) | 0.06% -0.022 pp | 0.02% +0.007 pp | USD29.79 +122.9% | 28 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
4
Shares acquired
—
Shares disposed
23.1K
Cash buys
—
Cash sales
4.00
Net activity
-23,095
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Hamilton James C | Officer | S-Sale | D | Common Stock | 10,000 | 75.00 | 750.0K | 226,958 | D | ↗ |
| 2026-04-22 | Apel Daniel Joseph | Officer | S-Sale | D | Common Stock | 3,208 | 70.11 | 224.9K | 172,792 | D | ↗ |
| 2026-03-05 | Hamilton James C | Officer | S-Sale | D | Common Stock | 10,000 | 64.19 | 641.9K | 236,958 | D | ↗ |
| 2026-01-06 | O'Brien Patrick | Officer | G-Gift | D | Common Stock | 540 | 0.00 | — | 474,368 | D | ↗ |
| 2026-01-06 | Hamilton James C | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 246,958 | D | ↗ |
| 2026-01-06 | Apel Daniel Joseph | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 176,200 | D | ↗ |
| 2026-01-05 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 313 | 68.00 | 21.3K | 484,663 | D | ↗ |
| 2026-01-05 | Hamilton James C | Officer | S-Sale | D | Common Stock | 309 | 68.00 | 21.0K | 171,958 | D | ↗ |
| 2026-01-02 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 7,416 | 65.88 | 488.6K | 3,798,510 | D | ↗ |
| 2025-12-31 | O'Brien Patrick | Officer | G-Gift | D | Common Stock | 560 | 0.00 | — | 524,401 | D | ↗ |
| 2025-12-29 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 35,181 | 69.33 | 2.44M | 3,822,471 | D | ↗ |
| 2025-12-26 | Ferrari Mauro | Director | S-Sale | D | Common Stock | 7,530 | 70.00 | 527.1K | 69,053 | D | ↗ |
| 2025-12-22 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 2,574 | 68.85 | 177.2K | 3,805,926 | D | ↗ |
| 2025-12-19 | Waddill William D. | Director | S-Sale | D | Common Stock | 500 | 68.53 | 34.3K | 56,563 | D | ↗ |
| 2025-12-19 | Vakiener Victoria | Director | S-Sale | D | Common Stock | 1,960 | 68.39 | 134.0K | 35,723 | D | ↗ |
| 2025-12-19 | OLUKOTUN ADEOYE Y | Director | S-Sale | D | Common Stock | 827 | 68.48 | 56.6K | 33,600 | D | ↗ |
| 2025-12-19 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 8,147 | 68.01 | 554.1K | 3,819,831 | D | ↗ |
| 2025-12-17 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 35,750 | 64.51 | 2.31M | 3,834,920 | D | ↗ |
| 2025-12-16 | Waddill William D. | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 64,930 | D | ↗ |
| 2025-12-16 | Vakiener Victoria | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 45,763 | D | ↗ |
| 2025-12-16 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 123,059 | D | ↗ |
| 2025-12-16 | OLUKOTUN ADEOYE Y | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 43,600 | D | ↗ |
| 2025-12-16 | Lu Hongbo | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 54,982 | D | ↗ |
| 2025-12-16 | INGRAM DOUGLAS S | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 46,215 | D | ↗ |
| 2025-12-16 | Ferrari Mauro | Director | A-Award | A | Common Stock | 7,819 | 0.00 | — | 76,583 | D | ↗ |
| 2025-12-16 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 8,416 | 60.51 | 509.3K | 3,962,839 | D | ↗ |
| 2025-12-15 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 21,321 | 69.28 | 1.48M | 3,979,402 | D | ↗ |
| 2025-12-12 | Anzalone Christopher Richard | Director / Officer | A-Award | A | Common Stock | 180,000 | 0.00 | — | 4,101,255 | D | ↗ |
| 2025-12-05 | PERRY MICHAEL S | Director | S-Sale | D | Common Stock | 16,250 | 61.03 | 991.7K | 115,240 | D | ↗ |
| 2025-11-28 | Ferrari Mauro | Director | S-Sale | D | Common Stock | 8,750 | 56.39 | 493.4K | 68,764 | D | ↗ |
| 2025-10-01 | Hamilton James C | Officer | S-Sale | D | Common Stock | 20,000 | 35.00 | 700.0K | 212,122 | D | ↗ |
| 2025-09-12 | Hamilton James C | Officer | S-Sale | D | Common Stock | 15,000 | 30.00 | 450.0K | 232,122 | D | ↗ |
| 2025-09-02 | Hamilton James C | Officer | S-Sale | D | Common Stock | 15,000 | 25.00 | 375.0K | 247,122 | D | ↗ |
| 2025-08-15 | Hamilton James C | Officer | S-Sale | D | Common Stock | 9,389 | 20.00 | 187.8K | 262,122 | D | ↗ |
| 2025-08-13 | Hamilton James C | Officer | S-Sale | D | Common Stock | 611 | 20.00 | 12.2K | 271,511 | D | ↗ |
| 2025-04-15 | Apel Daniel Joseph | Officer | — | — | Common Stock | 0 | 0.00 | — | 101,200 | D | ↗ |
| 2025-04-11 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 50,800 | 11.49 | 583.7K | 3,921,255 | D | ↗ |
| 2025-04-10 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 50,000 | 10.87 | 543.5K | 3,972,055 | D | ↗ |
| 2025-04-09 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 3,400 | 10.75 | 36.6K | 4,023,672 | D | ↗ |
| 2025-03-13 | Anzalone Christopher Richard | Director / Officer | A-Award | A | Common Stock | 340,000 | 0.00 | — | 4,113,802 | D | ↗ |
| 2025-03-04 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 133,333 | 17.02 | 2.27M | 3,773,802 | D | ↗ |
| 2025-03-03 | Anzalone Christopher Richard | Director / Officer | M-Exempt | D | Stock Option (right to buy Common Stock) | 133,333 | 7.75 | 1.03M | 51,726 | D | ↗ |
| 2025-02-07 | Anzalone Christopher Richard | Director / Officer | A-Award | A | Common Stock | 9,550 | 20.10 | 192.0K | 3,773,802 | D | ↗ |
| 2025-02-06 | INGRAM DOUGLAS S | Director | A-Award | A | Common Stock | 38,396 | 20.09 | 771.4K | 38,396 | D | ↗ |
| 2025-01-23 | OLUKOTUN ADEOYE Y | Director | S-Sale | D | Common Stock | 959 | 21.00 | 20.1K | 35,781 | D | ↗ |
| 2025-01-07 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 8,000 | 19.69 | 157.5K | 527,201 | D | ↗ |
| 2025-01-07 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 8,000 | 19.70 | 157.6K | 465,433 | D | ↗ |
| 2025-01-06 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 9,526 | 20.10 | 191.5K | 535,201 | D | ↗ |
| 2025-01-06 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 9,402 | 20.10 | 189.0K | 473,433 | D | ↗ |
| 2025-01-06 | Hamilton James C | Officer | S-Sale | D | Common Stock | 21,758 | 19.68 | 428.2K | 283,093 | D | ↗ |
| 2025-01-04 | O'Brien Patrick | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 564,385 | D | ↗ |
| 2025-01-04 | Myszkowski Kenneth Allen | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 500,600 | D | ↗ |
| 2025-01-04 | Hamilton James C | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 304,851 | D | ↗ |
| 2025-01-02 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 11,520 | 19.05 | 219.5K | 3,764,252 | D | ↗ |
| 2024-12-27 | OLUKOTUN ADEOYE Y | Director | S-Sale | D | Common Stock | 2,850 | 20.00 | 57.0K | 36,740 | D | ↗ |
| 2024-12-23 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 12,563 | 19.59 | 246.1K | 3,775,772 | D | ↗ |
| 2024-12-18 | Waddill William D. | Director | A-Award | A | Common Stock | 16,733 | 22.99 | 384.7K | 57,111 | D | ↗ |
| 2024-12-18 | Vakiener Victoria | Director | A-Award | A | Common Stock | 16,733 | 22.99 | 384.7K | 37,944 | D | ↗ |
| 2024-12-18 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 16,733 | 22.99 | 384.7K | 131,490 | D | ↗ |
| 2024-12-18 | OLUKOTUN ADEOYE Y | Director | A-Award | A | Common Stock | 16,733 | 22.99 | 384.7K | 39,590 | D | ↗ |
| 2024-12-18 | Lu Hongbo | Director | A-Award | A | Common Stock | 16,733 | 22.99 | 384.7K | 47,163 | D | ↗ |
| 2024-12-18 | Ferrari Mauro | Director | A-Award | A | Common Stock | 16,733 | 22.99 | 384.7K | 77,514 | D | ↗ |
| 2024-12-18 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 5,799 | 22.12 | 128.3K | 3,688,335 | D | ↗ |
| 2024-12-17 | Waddill William D. | Director | S-Sale | D | Common Stock | 3,747 | 22.04 | 82.6K | 40,378 | D | ↗ |
| 2024-12-17 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 547 | 22.04 | 12.1K | 124,167 | D | ↗ |
| 2024-12-16 | Waddill William D. | Director | S-Sale | D | Common Stock | 3,748 | 21.90 | 82.1K | 44,125 | D | ↗ |
| 2024-12-16 | Vakiener Victoria | Director | S-Sale | D | Common Stock | 8,994 | 21.91 | 197.1K | 21,211 | D | ↗ |
| 2024-12-16 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 5,000 | 21.90 | 109.5K | 124,714 | D | ↗ |
| 2024-09-30 | Lu Hongbo | Director | — | — | Common Stock | 0 | 0.00 | — | 5,650 | I | ↗ |
| 2024-07-02 | Oliver Tracie | Officer | S-Sale | D | Common Stock | 9,394 | 25.28 | 237.5K | 127,107 | — | ↗ |
| 2024-05-02 | Vakiener Victoria | Director | S-Sale | D | Common Stock | 1,799 | 23.31 | 41.9K | 30,205 | — | ↗ |
| 2024-04-01 | Hamilton James C | Officer | S-Sale | D | Common Stock | 6,000 | 28.03 | 168.2K | 204,851 | — | ↗ |
| 2024-03-20 | Lu Hongbo | Director | P-Purchase | A | Common Stock | 1,000 | 27.50 | 27.5K | 33,680 | — | ↗ |
| 2024-03-19 | Lu Hongbo | Director | P-Purchase | A | Common Stock | 1,000 | 28.00 | 28.0K | 32,680 | — | ↗ |
| 2024-03-18 | Lu Hongbo | Director | P-Purchase | A | Common Stock | 1,000 | 27.49 | 27.5K | 31,680 | — | ↗ |
| 2024-03-15 | Lu Hongbo | Director | — | D | Common Stock | 0 | 0.00 | — | 30,680 | — | ↗ |
| 2024-03-06 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 40,000 | 35.19 | 1.41M | 400,600 | — | ↗ |
| 2024-01-31 | Anzalone Christopher Richard | Director / Officer | M-Exempt | A | Common Stock | 57,499 | 14.54 | 836.0K | 3,772,547 | — | ↗ |
| 2024-01-12 | Hamilton James C | Officer | S-Sale | D | Common Stock | 4,238 | 36.47 | 154.6K | 214,553 | — | ↗ |
| 2024-01-11 | Waddill William D. | Director | S-Sale | D | Common Stock | 1,300 | 38.59 | 50.2K | 47,870 | — | ↗ |
| 2024-01-11 | Vakiener Victoria | Director | S-Sale | D | Common Stock | 3,620 | 37.87 | 137.1K | 33,101 | — | ↗ |
| 2024-01-11 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 1,811 | 37.76 | 68.4K | 130,811 | — | ↗ |
| 2024-01-11 | Ferrari Mauro | Director | S-Sale | D | Common Stock | 1,000 | 38.63 | 38.6K | 60,778 | — | ↗ |
| 2024-01-05 | San Martin Javier | Officer | S-Sale | D | Common Stock | 3,100 | 35.03 | 108.6K | 202,900 | — | ↗ |
| 2024-01-05 | Oliver Tracie | Officer | S-Sale | D | Common Stock | 74 | 33.89 | 2.5K | 136,501 | — | ↗ |
| 2024-01-05 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 12,741 | 35.65 | 454.2K | 464,385 | — | ↗ |
| 2024-01-05 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 8,904 | 35.65 | 317.4K | 440,600 | — | ↗ |
| 2024-01-05 | Hamilton James C | — | S-Sale | D | Common Stock | 12,343 | 35.65 | 440.0K | 228,791 | — | ↗ |
| 2024-01-04 | San Martin Javier | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 206,800 | — | ↗ |
| 2024-01-04 | Oliver Tracie | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 136,575 | — | ↗ |
| 2024-01-04 | O'Brien Patrick | Officer | A-Award | A | Common Stock | 85,000 | 0.00 | — | 487,226 | — | ↗ |
| 2024-01-04 | Myszkowski Kenneth Allen | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 456,704 | — | ↗ |
| 2024-01-04 | Hamilton James C | — | A-Award | A | Common Stock | 75,000 | 0.00 | — | 250,934 | — | ↗ |
| 2024-01-03 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 3,849 | 31.83 | 122.5K | 408,726 | — | ↗ |
| 2024-01-03 | Hamilton James C | — | S-Sale | D | Common Stock | 500 | 33.30 | 16.7K | 175,934 | — | ↗ |
| 2024-01-02 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 4,634 | 30.74 | 142.4K | 3,720,366 | — | ↗ |
| 2023-12-20 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 12,000 | 28.54 | 342.5K | 3,725,000 | — | ↗ |
| 2023-12-15 | Waddill William D. | Director | A-Award | A | Common Stock | 14,987 | 25.41 | 380.8K | 51,804 | — | ↗ |
| 2023-12-15 | Vakiener Victoria | Director | A-Award | A | Common Stock | 14,987 | 25.41 | 380.8K | 36,721 | — | ↗ |
| 2023-12-15 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 14,987 | 25.41 | 380.8K | 114,754 | — | ↗ |
| 2023-12-15 | OLUKOTUN ADEOYE Y | Director | A-Award | A | Common Stock | 14,987 | 25.41 | 380.8K | 22,854 | — | ↗ |
| 2023-12-15 | GIVEN DOUGLAS B | Director | A-Award | A | Common Stock | 14,987 | 25.41 | 380.8K | 132,622 | — | ↗ |
| 2023-12-15 | Ferrari Mauro | Director | A-Award | A | Common Stock | 14,987 | 25.41 | 380.8K | 65,825 | — | ↗ |
| 2023-11-20 | San Martin Javier | Officer | S-Sale | D | Common Stock | 14,758 | 28.73 | 424.0K | 136,742 | — | ↗ |
| 2023-10-25 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 24,338 | 24.21 | 589.2K | 3,737,000 | — | ↗ |
| 2023-09-28 | Vakiener Victoria | Director | S-Sale | D | Common Stock | 1,550 | 26.33 | 40.8K | 21,734 | — | ↗ |
| 2023-09-18 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 31,523 | 28.00 | 882.6K | 3,787,570 | — | ↗ |
| 2023-07-03 | Oliver Tracie | Officer | S-Sale | D | Common Stock | 8,925 | 35.31 | 315.1K | 61,575 | — | ↗ |
| 2023-06-30 | Hamilton James C | — | S-Sale | D | Common Stock | 3,000 | 35.53 | 106.6K | 188,484 | — | ↗ |
| 2023-06-27 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 15,000 | 36.20 | 543.0K | 381,704 | — | ↗ |
| 2023-05-05 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 6,500 | 40.90 | 265.9K | 117,635 | — | ↗ |
| 2023-05-04 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 25,992 | 40.02 | 1.04M | 3,761,338 | — | ↗ |
| 2023-05-03 | Anzalone Christopher Richard | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 54,928 | 2.01 | 110.4K | 516,980 | — | ↗ |
| 2023-03-03 | OLUKOTUN ADEOYE Y | Director | S-Sale | D | Common Stock | 11,350 | 32.65 | 370.6K | 7,867 | — | ↗ |
| 2023-02-27 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 875 | 32.62 | 28.5K | 13,000 | — | ↗ |
| 2023-01-10 | Waddill William D. | Director | A-Award | A | Common Stock | 4,593 | 0.00 | — | 4,593 | — | ↗ |
| 2023-01-10 | Vakiener Victoria | Director | A-Award | A | Common Stock | 4,593 | 0.00 | — | 4,593 | — | ↗ |
| 2023-01-10 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 7,867 | 0.00 | — | 99,767 | — | ↗ |
| 2023-01-10 | OLUKOTUN ADEOYE Y | Director | A-Award | A | Common Stock | 7,867 | 0.00 | — | 19,217 | — | ↗ |
| 2023-01-10 | GIVEN DOUGLAS B | Director | A-Award | A | Common Stock | 4,593 | 0.00 | — | 4,593 | — | ↗ |
| 2023-01-10 | Ferrari Mauro | Director | A-Award | A | Common Stock | 4,593 | 0.00 | — | 4,593 | — | ↗ |
| 2023-01-10 | De Backer Marianne | Director | A-Award | A | Common Stock | 4,593 | 0.00 | — | 4,593 | — | ↗ |
| 2023-01-09 | Waddill William D. | Director | S-Sale | D | Common Stock | 3,200 | 30.00 | 96.0K | 28,950 | — | ↗ |
| 2023-01-05 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 7,500 | 37.39 | 280.4K | 413,375 | — | ↗ |
| 2023-01-05 | Hamilton James C | Director | S-Sale | D | Common Stock | 7,230 | 37.40 | 270.4K | 198,057 | — | ↗ |
| 2023-01-04 | San Martin Javier | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 151,500 | — | ↗ |
| 2023-01-04 | Oliver Tracie | Officer | A-Award | A | Common Stock | 500 | 0.00 | — | 70,500 | — | ↗ |
| 2023-01-04 | O'Brien Patrick | Officer | A-Award | A | Common Stock | 65,000 | 0.00 | — | 428,375 | — | ↗ |
| 2023-01-04 | Myszkowski Kenneth Allen | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 396,704 | — | ↗ |
| 2023-01-04 | Hamilton James C | Director | A-Award | A | Common Stock | 60,000 | 0.00 | — | 205,287 | — | ↗ |
| 2023-01-03 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 70 | 40.80 | 2.9K | 372,125 | — | ↗ |
| 2023-01-03 | Hamilton James C | Director | S-Sale | D | Common Stock | 300 | 39.56 | 11.9K | 145,534 | — | ↗ |
| 2022-12-29 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 30,625 | 40.00 | 1.23M | 336,704 | — | ↗ |
| 2022-12-21 | O'Brien Patrick | Officer | M-Exempt | A | Common Stock | 32,000 | 6.15 | 196.8K | 380,875 | — | ↗ |
| 2022-12-20 | Anzalone Christopher Richard | Officer | A-Award | A | Common Stock | 234,025 | 0.00 | — | 3,720,714 | — | ↗ |
| 2022-12-16 | Anzalone Christopher Richard | Officer | A-Award | A | Common Stock | 18,375 | 0.00 | — | 3,486,689 | — | ↗ |
| 2022-11-21 | San Martin Javier | Officer | S-Sale | D | COMMON STOCK | 200 | 30.62 | 6.1K | 91,500 | — | ↗ |
| 2022-09-30 | Myszkowski Kenneth Allen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-27 | Anzalone Christopher Richard | Director / Officer | M-Exempt | D | Common Stock | 1,542 | 31.21 | 48.1K | 3,468,314 | — | ↗ |
| 2022-07-08 | Anzalone Christopher Richard | Officer | D-Return | D | Common Stock | 551,197 | 0.00 | — | 3,508,938 | — | ↗ |
| 2022-07-07 | Anzalone Christopher Richard | Director / Officer | M-Exempt | A | Common Stock | 2,501 | 14.54 | 36.4K | 4,060,135 | — | ↗ |
| 2022-05-02 | Vakiener Victoria | Director | — | D | Common Stock | 0 | 0.00 | — | 17,181 | — | ↗ |
| 2022-02-11 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 42,153 | 52.28 | 2.20M | 4,121,016 | — | ↗ |
| 2022-01-07 | Waddill William D. | Director | A-Award | A | Common Stock | 6,400 | 0.00 | — | 32,150 | — | ↗ |
| 2022-01-07 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 6,400 | 0.00 | — | 91,900 | — | ↗ |
| 2022-01-07 | OLUKOTUN ADEOYE Y | Director | A-Award | A | Common Stock | 6,400 | 0.00 | — | 11,350 | — | ↗ |
| 2022-01-07 | GIVEN DOUGLAS B | Director | A-Award | A | Common Stock | 6,400 | 0.00 | — | 116,268 | — | ↗ |
| 2022-01-07 | Ferrari Mauro | Director | A-Award | A | Common Stock | 6,400 | 0.00 | — | 42,971 | — | ↗ |
| 2022-01-07 | De Backer Marianne | Director | A-Award | A | Common Stock | 6,400 | 0.00 | — | 23,400 | — | ↗ |
| 2022-01-07 | Anzalone Christopher Richard | Director / Officer | M-Exempt | A | Common Stock | 11,806 | 5.19 | 61.3K | 4,057,634 | — | ↗ |
| 2022-01-05 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 5,000 | 62.49 | 312.5K | 353,591 | — | ↗ |
| 2022-01-05 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 3,778 | 63.17 | 238.7K | 467,791 | — | ↗ |
| 2022-01-05 | Hamilton James C | — | S-Sale | D | Common Stock | 700 | 63.68 | 44.6K | 155,685 | — | ↗ |
| 2022-01-04 | Hamilton James C | — | S-Sale | D | Common Stock | 500 | 69.38 | 34.7K | 161,875 | — | ↗ |
| 2022-01-03 | Waddill William D. | Director | S-Sale | D | Common Stock | 272 | 66.25 | 18.0K | 25,750 | — | ↗ |
| 2022-01-03 | PERRY MICHAEL S | Director | S-Sale | D | Common Stock | 1,600 | 65.12 | 104.2K | 85,772 | — | ↗ |
| 2022-01-03 | OLUKOTUN ADEOYE Y | Director | S-Sale | D | Common Stock | 1,890 | 64.26 | 121.5K | 7,110 | — | ↗ |
| 2022-01-03 | De Backer Marianne | Director | S-Sale | D | Common Stock | 272 | 66.25 | 18.0K | 17,000 | — | ↗ |
| 2022-01-01 | O'Brien Patrick | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 381,375 | — | ↗ |
| 2022-01-01 | Myszkowski Kenneth Allen | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 504,005 | — | ↗ |
| 2022-01-01 | Hamilton James C | — | A-Award | A | Common Stock | 55,000 | 0.00 | — | 181,250 | — | ↗ |
| 2022-01-01 | Anzalone Christopher Richard | Director / Officer | A-Award | A | Common Stock | 800,000 | 0.00 | — | 4,045,828 | — | ↗ |
| 2021-12-31 | O'Brien Patrick | Officer | M-Exempt | A | Common Stock | 28,000 | 6.15 | 172.2K | 321,375 | — | ↗ |
| 2021-12-28 | GIVEN DOUGLAS B | Director | P-Purchase | A | Common Stock | 655 | 66.37 | 43.5K | 109,868 | — | ↗ |
| 2021-12-28 | Ferrari Mauro | Director | S-Sale | D | Common Stock | 3,400 | 66.82 | 227.2K | 36,571 | — | ↗ |
| 2021-12-23 | Anzalone Christopher Richard | Director / Officer | M-Exempt | D | Stock Option (right to buy Common Stock) | 11,806 | 5.19 | 61.3K | 773,227 | — | ↗ |
| 2021-12-15 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 25,857 | 66.28 | 1.71M | 3,253,165 | — | ↗ |
| 2021-11-19 | San Martin Javier | Officer | S-Sale | D | Common Stock | 13,704 | 69.01 | 945.7K | 116,796 | — | ↗ |
| 2021-10-22 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 5,830 | 66.09 | 385.3K | 3,279,022 | — | ↗ |
| 2021-10-20 | Anzalone Christopher Richard | Director / Officer | S-Sale | D | Common Stock | 15,000 | 66.23 | 993.5K | 3,329,022 | — | ↗ |
| 2021-09-13 | OLUKOTUN ADEOYE Y | Director | S-Sale | D | Common Stock | 2,250 | 63.76 | 143.5K | 11,750 | — | ↗ |
| 2021-09-09 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 5,000 | 65.24 | 326.2K | 109,868 | — | ↗ |
| 2021-06-24 | De Backer Marianne | Director | S-Sale | D | Common Stock | 5,000 | 89.85 | 449.3K | 21,500 | — | ↗ |
| 2021-06-22 | Hassard James | Officer | S-Sale | D | Common Stock | 3,625 | 89.22 | 323.4K | 105,750 | — | ↗ |
| 2021-06-22 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 4,500 | 89.21 | 401.4K | 114,868 | — | ↗ |
| 2021-02-22 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 1,125 | 88.73 | 99.8K | 13,875 | — | ↗ |
| 2021-02-08 | O'Brien Patrick | Officer | M-Exempt | D | Stock Option (right to buy) | 90,000 | 5.22 | 469.8K | 60,000 | — | ↗ |
| 2021-01-15 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 3,000 | 83.28 | 249.8K | 12,500 | — | ↗ |
| 2021-01-14 | Hamilton James C | — | S-Sale | D | Common Stock | 3,814 | 81.82 | 312.1K | 126,250 | — | ↗ |
| 2021-01-12 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 1,441 | 81.00 | 116.7K | 444,005 | — | ↗ |
| 2021-01-11 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 11,597 | 81.02 | 939.6K | 445,446 | — | ↗ |
| 2021-01-07 | Hassard James | Officer | S-Sale | D | Common Stock | 15,625 | 75.00 | 1.17M | 109,375 | — | ↗ |
| 2021-01-06 | O'Brien Patrick | Officer | S-Sale | D | Common Stock | 1,142 | 70.78 | 80.8K | 317,233 | — | ↗ |
| 2021-01-06 | Myszkowski Kenneth Allen | Officer | S-Sale | D | Common Stock | 1,100 | 70.75 | 77.8K | 486,568 | — | ↗ |
| 2021-01-06 | Hamilton James C | — | S-Sale | D | Common Stock | 700 | 70.89 | 49.6K | 154,925 | — | ↗ |
| 2021-01-05 | Hamilton James C | — | S-Sale | D | Common Stock | 1,925 | 73.93 | 142.3K | 155,625 | — | ↗ |
| 2021-01-04 | Waddill William D. | Director | S-Sale | D | Common Stock | 3,750 | 76.08 | 285.3K | 30,250 | — | ↗ |
| 2021-01-04 | PERRY MICHAEL S | Director | S-Sale | D | Common Stock Sold | 4,000 | 76.09 | 304.4K | 90,000 | — | ↗ |
| 2021-01-04 | GIVEN DOUGLAS B | Director | S-Sale | D | Common Stock | 4,000 | 76.08 | 304.3K | 119,368 | — | ↗ |
| 2021-01-01 | Waddill William D. | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 34,000 | — | ↗ |
| 2021-01-01 | PERRY MICHAEL S | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 94,000 | — | ↗ |
| 2021-01-01 | OLUKOTUN ADEOYE Y | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 14,000 | — | ↗ |
| 2021-01-01 | O'Brien Patrick | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 318,375 | — | ↗ |
| 2021-01-01 | Myszkowski Kenneth Allen | Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 487,668 | — | ↗ |
| 2021-01-01 | Hamilton James C | — | A-Award | A | Common Stock | 50,000 | 0.00 | — | 175,000 | — | ↗ |
| 2021-01-01 | GIVEN DOUGLAS B | Director | A-Award | A | Common Stock | 9,500 | 0.00 | — | 123,368 | — | ↗ |
| 2021-01-01 | Ferrari Mauro | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 39,971 | — | ↗ |
| 2021-01-01 | De Backer Marianne | Director | A-Award | A | Common Stock | 9,000 | 0.00 | — | 26,500 | — | ↗ |
| 2021-01-01 | Anzalone Christopher Richard | Director / Officer | A-Award | A | Common Stock | 800,000 | 0.00 | — | 3,344,022 | — | ↗ |
| 2020-12-30 | Anzalone Christopher Richard | Director / Officer | G-Gift | D | Common Stock | 599 | 0.00 | — | 2,544,022 | — | ↗ |
Executive team
Top executives
EBIT / Employee
231.4K
Shares Outstanding
140.03M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Christopher Anzalone President and Chief Executive Officer | 981.0K | — | 6.81M | — | 1.24M | 2.5K | 9.03M | 75.42% | ↗ |
| 2 | 2025 | Patrick O’Brien Chief Operating Officer | 653.9K | — | 1.98M | — | 365.6K | 31.6K | 3.03M | 65.31% | ↗ |
| 3 | 2025 | James Hamilton Chief Medical Officer | 617.5K | — | 1.98M | — | 354.6K | 15.1K | 2.97M | 66.72% | ↗ |
| 4 | 2025 | Kenneth Myszkowski Former Chief Financial Officer | 496.8K | — | 1.98M | — | 155.8K | 28.6K | 2.66M | 74.39% | ↗ |
| 5 | 2025 | Daniel Apel Chief Financial Officer | 232.2K | 200.0K | 1.29M | — | 226.4K | 9.3K | 1.75M | 73.34% | ↗ |
| 6 | 2025 | Tracie Oliver Former Chief Commercial Officer | 43.2K | — | — | — | — | — | 43.2K | 0.00% | ↗ |
| 7 | 2024 | Christopher Anzalone President and Chief Executive Officer | 951.0K | — | 10.32M | — | 1.15M | 2.4K | 12.42M | 83.05% | ↗ |
| 8 | 2024 | Patrick O’Brien Chief Operating Officer | 605.3K | — | 2.94M | — | 378.0K | 31.3K | 3.95M | 74.31% | ↗ |
| 9 | 2024 | Patrick O’Brien Chief Operating Officer and General Counsel | 605.3K | — | 2.94M | — | 378.0K | 15.3K | 3.93M | 74.62% | ↗ |
| 10 | 2024 | Kenneth Myszkowski Former Chief Financial Officer | 592.4K | — | 2.59M | — | 314.5K | 31.8K | 3.53M | 73.40% | ↗ |
| 11 | 2024 | Kenneth Myszkowski Chief Financial Officer | 592.4K | — | 2.59M | — | 314.5K | 15.8K | 3.51M | 73.73% | ↗ |
| 12 | 2024 | James Hamilton Chief Medical Officer | 567.9K | — | 2.59M | — | 314.5K | 15.3K | 3.49M | 74.26% | ↗ |
| 13 | 2024 | James Hamilton Chief of Discovery and Translational Medicine | 567.9K | — | 2.59M | — | 314.5K | 15.3K | 3.49M | 74.26% | ↗ |
| 14 | 2024 | Javier San Martin Former Chief Medical Officer | 260.5K | — | 2.59M | — | — | 606.3K | 3.46M | 74.92% | ↗ |
| 15 | 2024 | Tracie Oliver Former Chief Commercial Officer | 484.1K | — | 2.59M | — | — | 3.0K | 3.08M | 84.17% | ↗ |
| 16 | 2023 | Christopher Anzalone President and Chief Executive Officer | 902.5K | — | 8.31M | — | 700.0K | 1.5K | 9.92M | 83.83% | ↗ |
| 17 | 2023 | Patrick O’Brien Chief Operating Officer | 568.4K | — | 2.48M | — | 252.0K | 30.7K | 3.33M | 74.41% | ↗ |
| 18 | 2023 | Patrick O’Brien Chief Operating Officer and General Counsel | 568.4K | — | 2.48M | — | 252.0K | 14.7K | 3.31M | 74.77% | ↗ |
| 19 | 2023 | Kenneth Myszkowski Former Chief Financial Officer | 568.1K | — | 2.28M | — | 252.0K | 30.2K | 3.14M | 72.88% | ↗ |
| 20 | 2023 | Kenneth Myszkowski Chief Financial Officer | 568.1K | — | 2.28M | — | 252.0K | 14.2K | 3.12M | 73.25% | ↗ |
| 21 | 2023 | Javier San Martin Former Chief Medical Officer | 544.5K | — | 2.28M | — | 252.0K | 14.7K | 3.10M | 73.80% | ↗ |
| 22 | 2023 | Javier San Martin Chief Medical Officer | 544.5K | — | 2.28M | — | 252.0K | 14.7K | 3.10M | 73.80% | ↗ |
| 23 | 2023 | James Hamilton Chief Medical Officer | 511.2K | — | 2.28M | — | 236.3K | 14.7K | 3.05M | 74.99% | ↗ |
| 24 | 2023 | James Hamilton Chief of Discovery and Translational Medicine | 511.2K | — | 2.28M | — | 236.3K | 14.7K | 3.05M | 74.99% | ↗ |
| 25 | 2023 | Tracie Oliver Former Chief Commercial Officer | 647.3K | — | 19.0K | — | 188.0K | 19.5K | 873.8K | 2.18% | ↗ |
| 26 | 2022 | Christopher Anzalone President and Chief Executive Officer | 863.4K | — | 10.38M | — | 783.3K | 2.7K | 12.03M | 86.29% | ↗ |
| 27 | 2022 | Kenneth Myszkowski Chief Financial Officer | 509.6K | — | 3.98M | — | 238.1K | 13.8K | 4.74M | 83.93% | ↗ |
| 28 | 2022 | Patrick O’Brien Chief Operating Officer and General Counsel | 500.5K | — | 3.98M | — | 235.6K | 13.8K | 4.73M | 84.14% | ↗ |
| 29 | 2022 | James Hamilton Chief of Discovery and Translational Medicine | 450.4K | — | 3.65M | — | 212.6K | 13.8K | 4.32M | 84.35% | ↗ |
| 30 | 2022 | Tracie Oliver Former Chief Commercial Officer | 111.2K | 16.3K | 2.52M | — | 94.9K | 4.9K | 2.74M | 91.72% | ↗ |
| 31 | 2022 | Tracie Oliver Chief Commercial Officer | 111.2K | 16.3K | 2.52M | — | 94.9K | 4.9K | 2.74M | 91.72% | ↗ |
| 32 | 2022 | Javier San Martin Former Chief Medical Officer | 479.2K | — | — | — | 225.6K | — | 704.7K | 0.00% | ↗ |
| 33 | 2022 | Javier San Martin Chief Medical Officer | 479.2K | — | — | — | 225.6K | — | 704.7K | 0.00% | ↗ |
| 34 | 2021 | Christopher Anzalone President and Chief Executive Officer | 837.0K | — | 23.02M | — | 845.0K | 2.8K | 24.70M | 93.18% | ↗ |
| 35 | 2021 | Patrick O’Brien General Counsel, Corp. Sect. and Chief Compliance Officer | 479.8K | — | 4.60M | — | 239.6K | 13.7K | 5.34M | 86.26% | ↗ |
| 36 | 2021 | Patrick O’Brien Chief Operating Officer and General Counsel | 479.8K | — | 4.60M | — | 239.6K | 13.7K | 5.34M | 86.26% | ↗ |
| 37 | 2021 | Kenneth Myszkowski Chief Financial Officer | 484.9K | — | 4.60M | — | 231.2K | 13.7K | 5.33M | 86.32% | ↗ |
| 38 | 2021 | James Hamilton Chief of Discovery and Translational Medicine | 426.1K | — | 3.84M | — | 233.6K | 13.7K | 4.51M | 85.07% | ↗ |
| 39 | 2021 | James Hamilton Sr. VP Discovery and Translational Medicine | 426.1K | — | 3.84M | — | 233.6K | 13.7K | 4.51M | 85.07% | ↗ |
| 40 | 2021 | James Hassard Chief Commercial Officer | 431.7K | — | — | — | — | 353.1K | 784.8K | 0.00% | ↗ |
| 41 | 2021 | Javier San Martin Chief Medical Officer | 459.3K | — | — | — | 185.4K | — | 644.7K | 0.00% | ↗ |
| 42 | 2020 | Bruce D. Given Former Chief Operating Officer | 409.6K | — | 15.86M | — | — | 76.7K | 16.34M | 97.02% | ↗ |
| 43 | 2020 | Christopher Anzalone President and Chief Executive Officer | 785.6K | — | 12.69M | — | 820.0K | 2.9K | 14.29M | 88.75% | ↗ |
| 44 | 2020 | James Hassard Chief Commercial Officer | 302.4K | — | 7.43M | — | 170.0K | 15.9K | 7.92M | 93.83% | ↗ |
| 45 | 2020 | Javier San Martin Chief Medical Officer | 380.8K | 100.0K | 7.23M | — | 180.0K | 12.8K | 7.90M | 91.47% | ↗ |
| 46 | 2020 | Curt Bradshaw Former Chief Scientific Officer | 338.5K | — | 6.02M | — | — | 13.5K | 6.37M | 94.48% | ↗ |
| 47 | 2020 | Kenneth Myszkowski Chief Financial Officer | 463.8K | — | 5.39M | — | 213.8K | 12.8K | 6.08M | 88.65% | ↗ |
| 48 | 2020 | Patrick O’Brien Chief Operating Officer and General Counsel | 459.1K | — | 4.44M | — | 211.5K | 12.8K | 5.12M | 86.66% | ↗ |
| 49 | 2020 | Patrick O’Brien General Counsel, Corp. Sect. and Chief Compliance Officer | 459.1K | — | 4.44M | — | 211.5K | 12.8K | 5.12M | 86.66% | ↗ |
| 50 | 2020 | James Hamilton Chief of Discovery and Translational Medicine | 376.4K | — | 2.85M | — | 169.4K | 12.8K | 3.41M | 83.63% | ↗ |
| 51 | 2020 | James Hamilton Sr. VP Discovery and Translational Medicine | 376.4K | — | 2.85M | — | 169.4K | 12.8K | 3.41M | 83.63% | ↗ |
| 52 | 2019 | Bruce D. Given Former Chief Operating Officer | 488.8K | — | 2.61M | — | 850.0K | 11.8K | 3.96M | 65.88% | ↗ |
| 53 | 2019 | Bruce D. Given Chief Operating Officer | 488.8K | — | 2.61M | — | 850.0K | 11.8K | 3.96M | 65.88% | ↗ |
| 54 | 2019 | Christopher Anzalone President and Chief Executive Officer | 674.4K | — | — | — | 1.54M | 1.9K | 2.22M | 0.00% | ↗ |
| 55 | 2019 | Kenneth Myszkowski Chief Financial Officer | 422.5K | — | 1.06M | — | 251.6K | 11.8K | 1.74M | 60.62% | ↗ |
| 56 | 2019 | Patrick O’Brien General Counsel, Corp. Sect. and Chief Compliance Officer | 422.3K | — | 869.4K | — | 249.4K | 11.8K | 1.55M | 55.98% | ↗ |
| 57 | 2019 | Patrick O’Brien General Counsel | 422.3K | — | 869.4K | — | 249.4K | 11.8K | 1.55M | 55.98% | ↗ |
| 58 | 2019 | James Hamilton Sr. VP Discovery and Translational Medicine | 351.8K | — | 745.2K | — | 109.6K | 11.5K | 1.22M | 61.17% | ↗ |
| 59 | 2019 | Zhen Li Senior Vice President, Chemistry and Non- Clinical Development | 150.3K | — | 931.5K | — | — | 4.2K | 1.09M | 85.77% | ↗ |
| 60 | 2018 | Christopher Anzalone President and Chief Executive Officer | 643.0K | — | — | — | 975.0K | 1.9K | 1.62M | 0.00% | ↗ |
| 61 | 2018 | Bruce D. Given Former Chief Operating Officer | 450.4K | — | 644.0K | — | 445.9K | 11.8K | 1.55M | 41.49% | ↗ |
| 62 | 2018 | Bruce D. Given Chief Operating Officer | 450.4K | — | 644.0K | — | 445.9K | 11.8K | 1.55M | 41.49% | ↗ |
| 63 | 2018 | Kenneth Myszkowski Chief Financial Officer | 384.8K | — | 276.0K | — | 180.0K | 12.2K | 853.0K | 32.36% | ↗ |
| 64 | 2018 | Patrick O’Brien General Counsel | 406.2K | — | 220.8K | — | 184.5K | 11.8K | 823.3K | 26.82% | ↗ |
| 65 | 2018 | Zhen Li Senior Vice President, Chemistry and Non- Clinical Development | 287.5K | — | 239.2K | — | 150.0K | 9.5K | 686.1K | 34.86% | ↗ |
| 66 | 2017 | Christopher Anzalone President and Chief Executive Officer | 616.1K | — | 537.9K | — | 715.4K | 1.9K | 1.87M | 28.75% | ↗ |
| 67 | 2017 | Bruce D. Given Chief Operating Officer | 432.3K | — | 589.0K | — | 351.3K | 11.6K | 1.38M | 42.55% | ↗ |
| 68 | 2017 | Patrick O’Brien General Counsel | 391.0K | — | 224.8K | — | 177.7K | 11.6K | 805.0K | 27.92% | ↗ |
| 69 | 2017 | Kenneth Myszkowski Chief Financial Officer | 336.1K | — | 224.8K | — | 152.7K | 11.8K | 725.4K | 30.98% | ↗ |
| 70 | 2017 | Zhen Li Senior Vice President, Chemistry and Non- Clinical Development | 247.4K | — | 131.8K | — | 120.0K | 6.8K | 506.0K | 26.04% | ↗ |
| 71 | 2017 | Peter Leone Vice President, Strategic Business Initiatives | 261.8K | — | 139.5K | — | 71.4K | 10.5K | 483.2K | 28.87% | ↗ |
| 72 | 2016 | Bruce D. Given Chief Operating Officer | 415.6K | — | 922.5K | 276.6K | 251.8K | 11.4K | 1.88M | 63.85% | ↗ |
| 73 | 2016 | Christopher Anzalone President and Chief Executive Officer | 592.4K | — | — | 368.8K | 448.6K | 1.9K | 1.41M | 26.13% | ↗ |
| 74 | 2016 | Kenneth Myszkowski Chief Financial Officer | 321.7K | — | 307.5K | 184.4K | 130.5K | 12.4K | 956.5K | 51.42% | ↗ |
| 75 | 2016 | Patrick O’Brien General Counsel | 375.9K | — | — | 276.6K | 170.8K | 11.4K | 834.7K | 33.13% | ↗ |
| 76 | 2016 | David L. Lewis Chief Scientific Officer | 270.1K | — | — | 391.8K | — | 11.3K | 673.3K | 58.20% | ↗ |
| 77 | 2016 | Peter Leone Vice President, Strategic Business Initiatives | 251.7K | — | — | 230.5K | 89.0K | 10.5K | 581.7K | 39.62% | ↗ |
| 78 | 2016 | Zhen Li Senior Vice President, Chemistry and Non- Clinical Development | 237.9K | — | — | 230.5K | 72.1K | 10.2K | 550.7K | 41.86% | ↗ |
| 79 | 2015 | Christopher Anzalone President and Chief Executive Officer | 564.9K | — | 751.0K | 426.8K | 575.1K | 1.9K | 2.32M | 50.77% | ↗ |
| 80 | 2015 | Bruce D. Given Chief Operating Officer | 396.4K | — | 1.13M | 312.1K | 282.5K | 11.4K | 2.13M | 67.58% | ↗ |
| 81 | 2015 | Kenneth Myszkowski Chief Financial Officer | 302.4K | — | 375.5K | 260.1K | 123.1K | 13.0K | 1.07M | 59.18% | ↗ |
| 82 | 2015 | Patrick O’Brien General Counsel | 286.4K | 125.0K | 156.6K | 315.0K | 146.0K | 12.0K | 1.04M | 45.30% | ↗ |
| 83 | 2015 | David L. Lewis Chief Scientific Officer | 245.2K | — | — | 520.2K | 87.4K | 10.7K | 863.4K | 60.25% | ↗ |
| 84 | 2015 | Peter Leone Vice President, Strategic Business Initiatives | 240.1K | — | — | 442.2K | 85.5K | 10.5K | 778.3K | 56.82% | ↗ |
| 85 | 2014 | Christopher Anzalone President and Chief Executive Officer | 543.6K | — | 3.05M | 553.7K | 664.0K | 1.4K | 4.82M | 74.90% | ↗ |
| 86 | 2014 | Bruce D. Given Chief Operating Officer | 384.2K | — | 1.82M | 461.4K | 233.0K | 14.9K | 2.91M | 78.29% | ↗ |
| 87 | 2014 | Kenneth Myszkowski Chief Financial Officer | 293.4K | — | 1.02M | 461.4K | 119.0K | 11.6K | 1.90M | 77.72% | ↗ |
| 88 | 2014 | David L. Lewis Chief Scientific Officer | 226.4K | — | — | 1.11M | 84.0K | 9.2K | 1.43M | 77.61% | ↗ |
| 89 | 2014 | Peter Leone Vice President, Program Management and Strategy | 222.8K | — | — | 415.3K | 32.0K | 9.6K | 679.7K | 61.10% | ↗ |
| 90 | 2013 | Christopher Anzalone President and Chief Executive Officer | 504.8K | — | — | 463.4K | 486.0K | 1.4K | 1.46M | 31.83% | ↗ |
| 91 | 2013 | Bruce D. Given Chief Operating Officer | 363.5K | — | — | 334.9K | 221.0K | 10.4K | 929.7K | 36.02% | ↗ |
| 92 | 2013 | Kenneth Myszkowski Chief Financial Officer | 277.6K | — | — | 173.7K | 113.0K | 9.6K | 574.0K | 30.27% | ↗ |
| 93 | 2013 | David L. Lewis Chief Scientific Officer | 199.6K | 43.2K | — | 216.8K | 86.0K | 8.5K | 554.1K | 39.13% | ↗ |
| 94 | 2013 | Peter Leone Vice President, Program Management and Strategy | 143.1K | — | — | 83.4K | — | 5.8K | 232.3K | 35.88% | ↗ |
| 95 | 2012 | Christopher Anzalone President and Chief Executive Officer | 473.0K | — | — | 811.7K | 200.0K | 1.4K | 1.49M | 54.62% | ↗ |
| 96 | 2012 | Bruce D. Given Chief Operating Officer | 317.0K | — | — | 605.4K | — | 10.2K | 932.6K | 64.92% | ↗ |
| 97 | 2012 | Bruce Given Chief Operating Officer | 317.0K | — | — | 605.4K | — | 9.5K | 931.9K | 64.97% | ↗ |
| 98 | 2012 | Kenneth Myszkowski Chief Financial Officer | 262.0K | — | — | 425.7K | 60.0K | 10.4K | 758.1K | 56.15% | ↗ |
| 99 | 2012 | David L. Lewis Chief Scientific Officer | 195.3K | 86.4K | — | 254.7K | — | 5.9K | 542.4K | 46.96% | ↗ |
| 100 | 2012 | Peter Leone Vice President, Program Management and Strategy | 55.8K | — | — | — | — | 2.6K | 58.4K | 0.00% | ↗ |
| 101 | 2006 | Leon Ekchian President | 147.7K | — | — | 133.3K | — | 250.0K | 397.7K | 33.52% | ↗ |
| 102 | 2006 | Joseph T. Kingsley Interim President Chief Financial Officer | 208.2K | — | — | 75.0K | — | — | 208.2K | 36.03% | ↗ |
| 103 | 2006 | R. Bruce Stewart Chief Executive Officer | 202.9K | — | — | 75.0K | — | — | 202.9K | 36.97% | ↗ |
| 104 | 2005 | Joseph T. Kingsley Chief Financial Officer | 190.1K | — | — | 400.0K | — | — | 190.1K | 210.42% | ↗ |
| 105 | 2005 | Joseph T. Kingsley Interim President Chief Financial Officer | 190.1K | — | — | 400.0K | — | — | 190.1K | 210.42% | ↗ |
| 106 | 2005 | R. Bruce Stewart Chief Executive Officer | 105.6K | — | — | 250.0K | — | — | 105.6K | 236.81% | ↗ |
| 107 | 2005 | Leon Ekchian President | — | — | — | — | — | — | — | — | ↗ |
| 108 | 2004 | R. Bruce Stewart President and Chief Executive Officer | 60.0K | — | — | — | — | — | 60.0K | 0.00% | ↗ |
| 109 | 2004 | R. Bruce Stewart Chief Executive Officer | 60.0K | — | — | 250.0K | — | — | 60.0K | 416.67% | ↗ |
| 110 | 2004 | Joseph T. Kingsley Chief Financial Officer | 11.3K | — | — | — | — | — | 11.3K | 0.00% | ↗ |
| 111 | 2004 | Leon Ekchian President | — | — | — | — | — | — | — | — | ↗ |
| 112 | 2003 | R. Bruce Stewart President and Chief Executive Officer | 25.0K | — | — | 250.0K | — | — | 25.0K | 1,000.00% | ↗ |
| 113 | 2003 | R. Bruce Stewart Chief Executive Officer | 25.0K | — | — | — | — | — | 25.0K | 0.00% | ↗ |
| 114 | 2003 | Joseph T. Kingsley Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 115 | 2003 | Leon Ekchian President | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher R. Anzalone | Chairman, Chief Executive Officer & President | 2M | — |
| Patrick O'Brien | Chief Operating Officer, General Counsel & Secretary | 1M | male |
| Daniel J. Apel | Chief Financial Officer | 1M | male |
| James C. Hamilton | Chief Medical Officer and Head of R&D | 987.2K | — |
| Bruce D. Given | Chief Medical Scientist | 486.3K | — |
| Aaron Tan | Head of Tax | — | — |
| Vincent Anzalone | Head of Investor Relations & Vice President | — | — |
| Howard Lovy | Director of Communications | — | male |
| Mark Davis | Founder and Founder & Director of Insert Therapeutics Inc & Calando | — | — |
| Mark Seefeld | Head of Toxicology & Vice President | — | — |
| Tao Pei | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-01-31 | 2023-02-24 | Daniel Goldman | NY10 | — | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ARWR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
